Arcellx Raises $115m To Advance Novel T-Cell Therapies

First CAR-T In Phase I, Second Construct Heading For Clinic

The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.

Coins and seeds in jars — Arcellx's series C round will fund its T-cell therapy pipeline's growth • Source: Shutterstock

Arcellx, Inc. closed a $115m series C venture capital round on 13 April that it will use to complete a Phase I clinical trial for its first chimeric antigen receptor T-cell (CAR-T) therapy and take the candidate into a Phase II trial. The funding also will support the first clinical trials for the company’s proprietary Antigen Receptor Complex (ARC) and Soluble protein antigen receptor X-linked (SparX) technologies, which together are used to generate controllable T-cells.

CEO Rami Elghandour explained in an interview with Scrip that both types of engineered T-cells use a D domain – a novel synthetic binding domain – to bind to antigens on cancer cells rather than a single chain variable fragment (scFv), which is the preferred choice of most other CAR-T therapies in development

Arcellx Raises $115m To Advance Novel T-Cell Therapies

First CAR-T In Phase I, Second Construct Heading For Clinic

More from Financing

More from Business